Fibrocell Science, Inc. Takes Active Role To Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group
7/23/2014 1:07:40 PM
EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it will present at the 2014 Patient Care Conference of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) as part of the company’s commitment to engage and support advocacy groups for patients with rare diseases. Held every other year, this educational forum brings together patients and their families to connect with one another and hear about new research for epidermolysis bullosa (EB). John Maslowski, vice president of scientific affairs at Fibrocell, will discuss the company’s commitment to genetically-modified, autologous human fibroblasts for the treatment of recessive dystrophic epidermolysis bullosa, RDEB, the most severe form of dystrophic EB. This year’s DebRA Patient Care Conference is scheduled for July 30 – August 2 in Nashville, Tenn.
Help employers find you! Check out all the jobs and post your resume.
comments powered by